Patients with NSCLC harboring EGFR mutations and treated with tyrosine kinase inhibitors (TKIs) achieved significantly prolonged progression-free survival (PFS) and/or overall survival (OS) compared to those receiving conventional chemotherapy (Zhong et al., 2021; Liu et al., 2021; Greenhalgh et al., 2021; Sperduto et al., 2017; Cadranel et al., 2012). This evidence concerns the gene EGFR and non-small cell lung carcinoma.